Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China

CompletedOBSERVATIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 13, 2024

Study Completion Date

December 13, 2024

Conditions
Acromegaly
Trial Locations (12)

100000

Peking Union Medical College Hospital (PUMCH), Beijing

Peking University Third Hospital (PUH3), Beijing

110000

The First Hospital of China Medical University (CMU1H), Shenyang

210000

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School (NJDTH), Nanjing

310000

The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), Hangzhou

325000

Affiliated Hospital of Wenzhou Medical University (FAHWMU), Wenzhou

410000

Xiangya Hospital Central South University (XYHCSU), Changsha

430000

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology (TJH HUST), Wuhan

450000

The First Affiliated Hospital of Zhengzhou University (FAHZZU), Zhengzhou

510000

The First Affiliated Hospital,Sun Yat-sen University (FAHSYSU), Guangzhou

610000

West China Hospital,Sichuan University (WCH), Chengdu

050000

The Second Hospital of Hebei Medical University (HB2H), Shijiazhuang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY